Ruxolitinib cream + Vehicle cream
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lichen Sclerosus
Conditions
Lichen Sclerosus
Trial Timeline
Nov 18, 2022 → Dec 21, 2023
NCT ID
NCT05593445About Ruxolitinib cream + Vehicle cream
Ruxolitinib cream + Vehicle cream is a phase 2 stage product being developed by Incyte for Lichen Sclerosus. The current trial status is completed. This product is registered under clinical trial identifier NCT05593445. Target conditions include Lichen Sclerosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06804811 | Phase 3 | Recruiting |
| NCT06959225 | Phase 3 | Recruiting |
| NCT06958211 | Phase 3 | Recruiting |
| NCT06548360 | Phase 3 | Recruiting |
| NCT06238817 | Phase 3 | Completed |
| NCT05764161 | Phase 3 | Completed |
| NCT05755438 | Phase 3 | Completed |
| NCT05635838 | Phase 2 | Completed |
| NCT05593432 | Phase 2 | Completed |
| NCT05593445 | Phase 2 | Completed |
| NCT04896385 | Phase 2 | Completed |
| NCT03745638 | Phase 3 | Completed |
| NCT03745651 | Phase 3 | Completed |
| NCT03099304 | Phase 2 | Completed |
Competing Products
12 competing products in Lichen Sclerosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LP-10 (Liposomal Tacrolimus) | Lipella Pharmaceuticals | Phase 2 | 44 |
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Baricitinib 4 milligram Oral Tablet | Eli Lilly | Phase 2 | 52 |
| pimecrolimus and clobetasol + clobetasol 0.05% cream | Novartis | Phase 2 | 52 |
| Pimecrolimus 1% cream | Novartis | Phase 2 | 52 |
| secukinumab 300 mg Q4W + secukinumab 300 mg Q2W | Novartis | Phase 2 | 52 |
| Apremilast + Placebo | Amgen | Phase 2 | 51 |
| Deucravacitinib | Bristol Myers Squibb | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Amevive (Alefacept) + Placebo | Biogen | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 49 |